title: Fetal tachycardia: a role for amiodarone as first- or second-line therapy?
abstract: BACKGROUND
  Fetal tachycardias result in serious prenatal and postnatal morbidity and mortality. Intrauterine treatment can improve prognosis dramatically and the therapeutic protocol is well defined. Currently, amiodarone is used as third-line therapy and is reserved for refractory cases.
  
  
  OBJECTIVE
  Our aim was to review the management and outcome of fetal tachycardia, giving particular consideration to the efficacy and safety of amiodarone therapy.
  
  
  METHODS
  This was a retrospective study of 24 consecutive cases of sustained fetal tachycardia, treated mainly with digoxin and/or amiodarone administered by the transplacental route.
  
  
  RESULTS
  The 24 fetal tachycardias comprised 16 supraventricular tachycardias with 1:1 atrioventricular conduction, seven atrial flutters and one ventricular tachycardia. Seven fetuses were hydropic and eight experienced less severe cardiac failure. Digoxin monotherapy converted 5/12 non-hydropic fetuses and 0/2 hydropic fetuses, with one intrauterine death. Amiodarone monotherapy converted 5/5 fetuses, including two hydropic fetuses: one ventricular tachycardia, two atrial flutters and two supraventricular tachycardias. When administered with digoxin, amiodarone converted all but two fetuses (7/9). No deaths were associated with amiodarone, but there was moderate morbidity, with six transient elevations of thyroid stimulating hormone at birth, two of which required short-term thyroid hormonal substitution therapy.
  
  
  CONCLUSIONS
  Maternal oral amiodarone seems to be effective and relatively safe, even in hydropic fetuses. We suggest that this treatment could be used earlier than is currently advised.
authors.affiliation: Fetal and pediatric cardiology unit, CHRU of Angers, 4, rue Larrey, 49933 Angers cedex 09, France. philpez@mac.com
authors.forename: Philippe Georges
authors.initials: PG
authors.lastname: Pézard
authors.forename: Françoise
authors.initials: F
authors.lastname: Boussion
authors.forename: Loïc
authors.initials: L
authors.lastname: Sentilhes
authors.forename: Catherine
authors.initials: C
authors.lastname: Lépinard
authors.forename: Marie-Hélène
authors.initials: MH
authors.lastname: Couvreur
authors.forename: Jacques
authors.initials: J
authors.lastname: Victor
authors.forename: Philippe
authors.initials: P
authors.lastname: Geslin
authors.forename: Philippe
authors.initials: P
authors.lastname: Descamps
mesh_terms: D000284:Administration, Oral; D000638:Amiodarone / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D005260:Female; D005315:Fetal Diseases / Q000188:drug therapy*; D006801:Humans; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D012189:Retrospective Studies; D013617:Tachycardia, Supraventricular / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D000889:Anti-Arrhythmia Agents; D000638:Amiodarone